Brain disease model of addiction: why is it so controversial?
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The “Personal View” by Hall, Carter, and Forlini1 questions the value of the BDMA (brain disease model of addiction) and claims that it is not supported by animal or neuroimaging evidence, that it has not helped deliver more effective treatments and that its impact on public policy have been modest. However, these claims are not supported by the evidence. First, preclinical and clinical studies have consistently delineated specific molecular and functional neuroplastic changes at the synaptic and circuitry level that are triggered by repeated drug exposure. These findings, along with ongoing research, are helping us understand the neurobiological processes associated with the loss of control, compulsive drug taking, inflexible behavior, and negative emotional states associated with addiction (Figure 1). Second, uncovering the molecular targets and circuits underlying addiction has already resulted in several effective medications (naloxone and acamprosate for alcoholism, buprenorphine-naloxone for opioid addiction; varenicline for tobacco addiction) and ongoing clinical trials are taking advantage of this knowledge to test new targets 2, 3. For the approved medications the effect sizes are similar to those associated with standard anti-depressant pharmacotherapies. This knowledge had also provided the basis for the use of stimulation techniques such as transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) and its variants, to strengthen circuits impaired by addiction with promising results 4, 5. It has also provided clinicians with a framework to guide targeted interventions to strengthen the impaired circuits (i.e., behavioral interventions to enhance self-control, reduce stress reactivity, improve mood). Finally, the statement that the effects of the BDMA framework on public policy are modest negates some major achievements, such as the passage in 2008 of the parity law (the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act, driven by the BDMA model) that requires medical insurance for the first time in the USA to cover costs associated with the treatment of addiction6. Finally, the mere framework of BDMA has benefits in treatment as it significantly diminishes the stigma attached with addiction and gives hope for recovery to those fighting this devastating disease. Figure 1 Conceptual Framework for Neurobiological Bases of the Transition to Substance Use Disorders We agree that in addiction, as is the case for any other medical condition, there is a severity dimension (incorporated into the recently revised classification of substance use disorders in the diagnostic statistical manual or DSM 5; 7), and that only a small percentage of those with a substance use disorder fall in the most severe category. However, we don’t understand the argument of why this fact should negate the value of the disease model in addiction. It is basic research that is helping us understand this severity dimension and the mechanisms underlying the transition from mild to severe addiction that one day might enable us to develop interventions to revert and/or revert those changes and to identify those who are at most risk when exposed to drugs to transition into a severe phenotype. In the meantime, research is already providing evidence that is guiding therapeutic interventions on the basis of the levels of severity8. Similarly, as for any other disease the largest impact at the population level is derived from interventions that prevent the emergence of the disease process in the first place. In the case of cancer this would entail, for example, the prevention of smoking, which connotes prevention of nicotine addiction. Translational research is a powerful engine of effective prevention: Understanding how genetic, developmental and environmental (including social) factors influence the vulnerability for substance use disorders helps develop better prevention strategies; particularly for those at highest risk for whom universal prevention strategies are not as effective. This can be well illustrated by the case of the very successful smoking prevention campaign that resulted in >50% reduction in smoking but has failed to prevent smoking in 18-20% of the population, presumably those who are the most vulnerable. So why is it that despite all the scientific evidence the BDMA is so frequently singled out for criticism as in the piece by Hall, Carter, and Forlini? We think it reflects in part our expectations that science should immediately translate into transforming solutions, which have not materialized for addiction nor for most of the other brain diseases. Yet, the value of basic research in diseases such as Alzheimer’s or schizophrenia has never been questioned, which leads us to ponder whether the difficulty relies in accepting as a bona fide disease one that erodes the neuronal circuits that enable us to exert free-will. Addiction is a complex disease of a complex brain; ignoring this fact will only hamper our efforts to find effective solutions through a comprehensive and systematic understanding of the underlying phenomena.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dinur-Klein, L., Dannon, P., Hadar, A., Rosenberg, O., Roth, Y., Kotler, M., & Zangen, A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.020 · Cited by 367
Research works printed but not linked: 6
- Hall, 2015, The brain disease model of addiction: is it supported by the evidence and has it delivered on its promises?, Lancet Psychiatry, 2, 105, 10.1016/S2215-0366(14)00126-6 · DOI · Paper page
- Kalivas, 2011, New medications for drug addiction hiding in glutamatergic neuroplasticity, Mol Psychiatry, 16, 974, 10.1038/mp.2011.46 · DOI · Paper page
- Koob, 2010, Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor, Curr Opin Investig Drugs, 11, 63
- Conti, 2014, Cognitive related electrophysiological changes induced by non-invasive cortical electrical stimulation in crack-cocaine addiction, Int J Neuropsychopharmacol, 17, 1465, 10.1017/S1461145714000522 · DOI
- Busch, 2014, The effects of federal parity on substance use disorder treatment, Am J Manag Care, 20, 76
- McLellan, 2014, The affordable care act and treatment for “substance use disorders:” implications of ending segregated behavioral healthcare, J Subst Abuse Treat, 46, 541, 10.1016/j.jsat.2014.02.001 · DOI
Cited by
Neurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008
Self-citationEthics of the Attention Economy: The Problem of Social Media Addiction
Bhargava, V. R., & Velasquez, M. (2021) · Business Ethics Quarterly · doi:10.1017/beq.2020.32 · Cited by 292
The Classification of Substance Use Disorders: Historical, Contextual, and Conceptual Considerations
Robinson, S., & Adinoff, B. (2016) · Behavioral Sciences · doi:10.3390/bs6030018 · Cited by 171
“While advocates of a strict disease model of pathology underlying SUDs point out important achievements including improved recognition of the neurobiological process involved in addiction as well as new pharmacotherapies for treating addiction [66], this conceptualization is still, today, not without its detractors [6…”
BackgroundNeurobiology of opioid dependence in creating addiction vulnerability
Evans, C. J., & Cahill, C. M. (2016) · F1000Research · doi:10.12688/f1000research.8369.1 · Cited by 146
Kelly, J. F., Greene, M. C., & Abry, A. (2021) · Addiction · doi:10.1111/add.15333 · Cited by 88
“There have been recent efforts to re-assert the notion of addiction as a ‘disease’ characterized by brain-related structural deficits and functional impairment [18] (e.”
Background
Metadata
- Authors
- Volkow, N. D., & Koob, G.
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 2
- Issue
- 8
- Pages
- 677-679
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W1857655303
- Cited by
- 192
- References
- 1
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain disease model of addiction: why is it so controversial? https://app.cochat.ai/papers/10.1016/s2215-0366(15)00236-9
- The paper
- Volkow, N. D., & Koob, G. (2015). Brain disease model of addiction: why is it so controversial? The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(15)00236-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.